v. August 15th, 2022
(brief version)

CURRICULUM VITAE

Kenneth Cusi, M.D., F.A.C.P., F.A.C.E.

Personal Information

Place of birth: Allentown, Pennsylvania, USA

Professional address:
University of Florida
1600 SW Archer Road, room H-2
Gainesville, Florida 32610
Phone: 352-273-8662 (office); fax: 352-273-7441; e-mail: Kenneth.Cusi@medicine.ufl.edu

Present Academic Rank and Position

2011 – present	Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism, Dept. of Medicine University of Florida at Gainesville

Previous Professional Appointments

2011-07/2022	Chief, Division of Endocrinology, Diabetes and Metabolism, Dept. of Medicine University of Florida at Gainesville
2013-2015	VA Acting Chief, Division of Endocrinology and Diabetes, Dept. of Medicine North Florida/South Georgia Veterans Health System Gainesville, Florida
2008-2011	Professor of Medicine, UTHSCSA
2002-2008	Associate Professor of Medicine, UTHSCSA
1997-2002	Assistant Professor of Medicine, Diabetes Division, UTHSCSA
1995-1997	Assistant Professor, Ctr. Med. Education & Clinical Research, Buenos Aires, Argentina & University of Buenos Aires, School of Medicine, Argentina
1993-1994	Assistant Professor, Diabetes Division, UTHSCSA

Postgraduate Education

1992-1993	Research Fellowship: Diabetes Division, UTHSCSA
1989-1992	Clinical Fellowship: Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas
1985-1988	Internship/Residency: Ctr. Med. Education & Clinical Research, Buenos Aires, Argentina

Graduate Education

1979-1984	University of Buenos Aires, School of Medicine, Buenos Aires, Argentina

Medical Licensure

2018	Florida license # ME111806

1988	FMGEMS: #429-398-1
1994	Texas license: #J5086

Board Certifications (ABIM, #190783):

1999-present	Internal Medicine (recertified until 2019)
2000-present	Endocrinology, Diabetes & Metabolism (recertified until 2020)

Honors and Awards

2020	American Association of Clinical Endocrinologists Jack Baskin, MD, Endocrine Teaching Award
2015 and 2016	University of Florida Department of Medicine Excellence in Teaching Award
2015	Clinical Research Award for outstanding achievement, research discovery, and productivity, University of Florida College of Medicine
2010-2016	Member of the American Diabetes Association's (ADA) Research Grant Review Committee (RGRC)
2010-present	Abstract reviewer for the AASLD Annual Scientific Sessions (topic: NASH)
2010-present	Member ad-hoc of the Metabolism Section and abstract reviewer for the ADA Annual Scientific Sessions Planning Committee
2009-2010	President, San Antonio, Texas ADA Chapter
2008-2009	President, Texas Chapter, American Association of Clinical Endocrinologists (AACE)
2007-2008	Vice-president, Texas AACE Chapter
2006-2008	Co-Chair, Metabolism Section, ADA Scientific Sessions Planning Committee
2007	Program Chair, AACE TX Chapter Annual Meeting (San Antonio, TX 8/2007)
2007	Chair, combined ADA/EASD plenary session on nonalcoholic fatty liver disease, ADA Annual Meeting, Chicago
2006-present	Fellow of the American College of Physicians (FACP)
2003-present	Fellow of the American Association of Clinical Endocrinologists (FACE)
1996	J.C. Fasciolo Award, Latin-American Hypertension Society
1995-1996	N. Quirno Award, Buenos Aires, Argentina
1994-1995	J.B. Craveri Award, Argentine Diabetes Association
1992-1995	Physician Recognition Award, American Medical Association.
1984	Diploma of Honor, University of Buenos Aires, School of Medicine, Argentina

Board of national professional organizations:

2016-present	Reviewer for the NIH Clinical and Integrative Diabetes and Obesity (CIDO) Study Section; Endocrinology, Metabolism, Nutrition and Reproductive Sciences Integrated Review Group.
2004-2011	Board member, Steering Committee of the Texas Chapter of AACE
2005-2011	Board member, Southwest Chapter of the National Lipid Association
2009-2010	President and Board member, San Antonio, Texas ADA Chapter
2004-2008	Board member, Minority Health Affairs Committee of AACE

Reviewer for the following medical journals: American J Physiology; Diabetes; Diabetologia; Diabetes Care; Diabetes, Obesity & Metabolism; Digestive Disease; Endocrine Practice; JCEM; Gastroenterology; Hepatology; J Hepatology; Liver International; others.
- On the Editorial Board of Diabetes Care, Metabolism.

Professional Affiliations
The American College of Physicians (ACP) – Fellow
The American Association of Clinical Endocrinologists (AACE) – Fellow
The American Association for the Study of Liver Disease (AASLD)
The American Diabetes Association
The Argentine Diabetes Society
The European Association for the Study of Diabetes (EASD)
The Endocrine Society

Trainees mentored by Dr. Cusi:

Trainee Name (Where Training Occurred)	Postdoc Research Training period	Prior Academic Degree(s)	Prior Academic Degree/ Institution	Research Project(s) and/or Publications (w/Dr. Cusi as PI)	Current position of past trainees/source of support of current trainees
Kaitlyn Abdo (Univ. Florida)	May 2015 to May 2017		UNC Wilmington		In training (Dr. Cusi's grants)
Srilaxmi Kalavalapalli (Univ. Florida)	May 2014 to present		India	Mechanisms of NAFLD (basic and clinical); 4 manuscripts (1 as first author).	In training (Dr. Cusi's grants)
Fernando Bril (Univ. Florida)	April 2013 to 2015	M.D.	Univ. of Buenos Aires, Argentina	5 first author manuscripts, 15 others as coauthor; 1 book chapter, 4 reviews.	Promoted to Asst. Professor at UF in 2015 .
Manisha Nautiyal (Univ. Florida)	March 2014 to March 2016	Ph.D.	India; Wake Forest, NC.	Pathogenesis of hepatic lipotoxicity in animal models of NASH. Two manuscripts.	Moved back to Wake Forest, NC, with faculty appointment.
Paola Portillo (Univ. Florida)	September 2014 to Febr 2016	M.D.	Mexico	Six original papers (one in press; 2 first author), 2 reviews.	Moved back to Mexico for clinical endocrine fellowship with commitment for faculty appointment.
Maryann Maximos (Univ. Florida)	August 2013 to June 2015	M.D.	Univ. of Florida	1 first author manuscript, 5 others as coauthor; 1 book chapter.	Assistant Professor, Pediatric GI Division (Univ. of Florida) since July 2015.

Carolina Ortiz-Lopez	2010-2013	M.D.	Colombia	1 first and 1 second author manuscripts; 4 others as coauthor	Residency (7/1/2013-present).
Romina Lomonaco (University of Texas HSC at San Antonio)	May 2009-September 2011	M.D.	Univ. of Corrientes, Argentina	3 first author manuscripts; 10 others as coauthor. Four reviews, 1 book chapter.	Assist Prof, Endocrine Div. (UF). Research faculty (2011-13). UF resident (2013-16); UF endocrine fellow (2016-18)
Manoj Mathew	2008-2010	M.D.	India	Second author in 1 manuscript, 5 others as coauthor.	Residency (7/1/2010-6/30/2013). Fellowship (7/1/2013-present).
Bogdan Balas	2006-2007	M.D.	Rumania	3 first author manuscripts; 1 book chapter.	Lead research scientist at Roche, Switzerland.
Y. Shaoyung	2009-2010	Ph.D.	China	1 first author manuscript, 1 other as coauthor	Returned to China
Renata Belfort	2002-2005	M.D.	Brazil	3 first author manuscripts (one in the NEJM 2006; 4 others as coauthor	Asst. Professor, Yale.
Sangeeta Kasyap	2003-2006	M.D.	India	3 first author manuscripts, 3 others as coauthor	Associate Professor, Cleveland Clinic.
Kelly Wirfel	2004-2006	M.D.	Univ. of Texas HSC at Houston, TX	1 second author manuscript (Diabetes 2005) and 2 as co-author.	Associate Professor, Univ. of Texas HSC at Houston, TX.
Pratima Kumar	2005-2006	M.D.	India	Second author in 1 manuscript, 5 others as coauthor.	Associate Professor, Univ. of Texas HSC at Austin, TX.
Thongchai Pratipanawatr	2000-2002	M.D.	Thailand	3 first author manuscripts, 3 others as coauthor	Faculty, Thailand

Bibliography

a) Reviews, editorials, letters and book chapters

1. Cusi K, Consoli A. Alcoholic ketoacidosis and lactic acidosis. *Diabetes Reviews* 1994, 2: 195-208
2. Cusi K, DeFronzo RA. Treatment of NIDDM, IDDM and other insulin resistant states with IGF-I. *Diabetes Reviews* 1995, 3: 206-236

3. Cusi K. Diabetic nephropathy. In the EPROCAD Textbook, by the Society for the Prevention of Peripheral Vascular Disease & CV Risk Factors in Diabetes Mellitus. Edit. AV Zabala, nº 1997, 1, (3)
4. Arem R and Cusi K. Thyroid function testing in psychiatric illness. Usefulness and limitations. *Trends in Endocrinology and Metabolism* 1997, 8: 282-287
5. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Reviews 1998, 6: 89-131
6. Cusi K, DeFronzo RA. Non-insulin dependent diabetes mellitus. In "The Endocrine Pancreas and Regulation of Metabolism", Handbook of Physiology, ed. LS Jefferson and AD Cherrington, *Oxford University Press* 2001, 1115-1168
7. Cusi, K. The role of insulin resistance in the pathogenesis of type 2 diabetes and cardiovascular disease. Implications for treatment. *Diabetes Care* 2000, 8-14
8. Cusi K. Diabetes mellitus, insulin and vanadyl sulfate. *Clinical Pearls* 2001, 11,8,132
9. Cusi, K. Cardiovascular risk management of the diabetic patient: from clinical trials to clinical practice. *The Endocrinologist* 2001, 11: 474-490
10. Zambon A, Cusi K. The role of fenofibrate in clinical practice. *Diabetes & Vascular Disease Research* 2007, S15-S20
11. Balas B, Ali R and Cusi K. Non-alcoholic steatohepatitis – an endocrine disorder. *Touch Briefings* 2007, 79-84
12. Cusi K. Managing atherogenic dyslipidemia in patients with high cardiovascular disease risk. *Epocrates* 2008
13. Cusi K. Nonalcoholic fatty liver disease (NAFLD): an overlooked complication of type 2 diabetes. *Practical Diabetology* 2008, 27: 18-24
14. Cusi K: Evolving concepts in lipotoxicity. *AASLD Postgraduate Course* 2008
15. Cusi K. The epidemic of type 2 diabetes mellitus: its links to obesity, insulin resistance and lipotoxicity. In textbook "Diabetes and Exercise". Editors Judith Regensteiner, Jane Reusch, Kerry Stewart and Aris Veves. *Humana Press Inc.* 2009, 3-54
16. Ali R & Cusi K. New diagnostic and treatment approaches in nonalcoholic fatty liver disease (NAFLD). *Annals of Medicine* 2009, 41: 265-278
17. Cusi K. Nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus. Current Opinion in Endocrinology. *Diabetes and Obesity* 2009, 16: 141-149
18. Cusi K: Lessons learned from studying families genetically predisposed to type 2 diabetes mellitus. *Current Diabetes Reports* 2009, 9: 200-207
19. Cusi K. Thiazolidinediones in NASH an odd couple meant to be? *J Clin Gastroenterol* 2009, 43:503-505
20. Cusi K: Role of liver insulin resistance and lipotoxicity in NASH. *Clinics in Liver* Disease 2009, 13: 545-563
21. Cusi K. New pharmacological approaches in type 2 diabetes mellitus. In textbook "Type 2 Diabetes Mellitus". Editors Manuel Serrano-Rios and Jose A. Gutierrez Fuentes. *Elsevier* 2009, 263-300
22. Cusi K. Role of adipose tissue insulin resistance and lipotoxicity in the development of type 2 diabetes mellitus. *Current Diabetes Reports* 2010, 10: 306-115
23. Cusi K, Ocampo G. Unmet needs in the Hispanic patient. *Amer J Med* 2011, S2-9

24. Cusi K. Comment on Hoeg et al. Lipid-induced insulin resistance in men and is not accompanied by inflammation or impaired proximal insulin signaling. *Diabetes* 2011 (letter).
25. Cusi K. The increased risk of type 2 diabetes in hispanic/latinos living in the United States. *Amer J Med* 2011 (editorial)
26. Lomonaco R, Chen J, Cusi K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). *Therapeutic Advances in Endocrinology and Metabolism* 2011, 2: 211-225
27. Harrison SA, Schenker S, Cusi K. Insulin sensitizers in nonalcoholic steatohepatitis. *Hepatology* 2011, 53: 1404-1405 (letter).
28. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications. *Gastroenterology* 2012, 142: 711-725
29. Bril F, Lomonaco R and Cusi K. The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. *Clin Lipidol* 2012, 7: 471-481
30. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 2012;142:1592-1609.
31. Lomonaco R, Sunny N, Bril F, Cusi K. Non-alcoholic fatty liver disease: Current issues and novel treatment approaches. *Drugs* 2013; 73:1-14.
32. Yau H, Rivera K, Lomonaco R, Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. *Curr Diab Rep* 2013;13:329-341.
33. Cusi K: NAFLD and diabetes. AASLD Postgraduate Course 2013.
34. Bril F, Ntim K, Lomonaco R, and Cusi K. Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). *International Textbook of Diabetes Mellitus*.2015. doi: 10.1002/9781118387658.ch20.
35. Rivera, K, Cusi, K, Edwards, C, Cosecreting adrenal tumor causing severe insulin resistance. *In Diabetes Case Studies.* Draznin, B, Low Wang CC, Rubin DJ, Eds. Alexandria VA American Diabetes Association;2015:124-129.
36. Bril F, Cusi K. Response to do ultrasonographic semi quantitative indices predict histological changes in NASH irrespective of steatosis extent? *Liver Int*. 2015;35:2341-2. doi: 10.1111/liv.12869.
37. Portillo-Sanchez, P, Cusi, K, Treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus. *Clinical Diabetes and Endocrinology* 2016;2:9. doi: 10.1186/s40842-016-0027-7.
38. Cusi, K, Commentary on the EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. *Practice UpdateI.* 2016.
39. Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. *Diabetologia* 2016, 59:1112-1120
40. Bril F, Cusi K. Nonalcoholic fatty liver disease: The new complication of type 2 diabetes mellitus. *Endocrinol Metab Clin North Am*. 2016;45:765-781.
41. Barb D, Portillo-Sanchez P, and Cusi K. Pharmacological management of nonalcoholic fatty liver disease. *Metabolism*. 2016;65:1183-1195.
42. Barb D, Cusi K, Reply to “statins and non-alcoholic steatohepatitis”, *Metabolism* (2016), http://dx.doi.org/10.1016/j.metabol.2016.10.004.

43. Edwards C, Cusi K. Prediabetes: A worldwide epidemic. *Endocrinol Metab Clin North Am* 2016;45:751-764.
44. Cusi K. Diabetes medications improve cardiovascular outcomes: the paradigm shifts. *Curr Opin Lipidol*. 2016;27:633-635.
45. Sunny NE, Bril F, Cusi K. Mitochondrial adaptation in nonalcoholic fatty liver disease: Novel mechanisms and treatment strategies.*Trends Endocrinol Metab.* 2017;28:250-260.
46. Williams RN, Filozof C, Goldstein BJ, Cusi K. Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program. *Clin Pharmacol Ther*. 2017; 101(4):444-446. doi:10.1002/cpt.560. Epub 2016 Nov 7.
47. Cusi K. Nonalcoholic steatohepatitis in non-obese patients: Not so different after all. *Hepatology*. 2017;65:4-7.
48. Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A call to action. *Diabetes Care*. 2017;40:419–430.
49. Bril F, Cusi K. Reply to: Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit. *Hepatology*. 2017 July. doi:10.1002/hep.29150. Epub 2017 Mar 13.
50. Cusi K. Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus. *Gut.* 2018 July;67(7). doi:10.1136/gutjnl-2017-313958. Epub 2017 Apr 13.
51. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of NAFLD: Practice guidance from the American Association for the Study of Liver Disease. *Hepatology*. 2018 Jan;67(1):328-357. doi:10.1002/hep.29367. Epub 2017 Jul 17.
52. Dhir G, Cusi K. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: A novel therapeutic option. *J Investig Med*. 2018;66(1):7-10. doi: 10.1136/jim-2017-000554. Epub 2017 Sep 15. Review.
53. Sabban E, Puchulu F, Cusi K. “Dermatology and Diabetes”. *Springer International Publishing AG*; 2018. doi: 10.1007/978-3-319-72475-1.
54. Leey J, Cusi K. Editorial: diabetes, obesity and clinical inertia-the recipe for advanced NASH. *Aliment Pharmacol Ther*. 2018, 47:1220-1221. doi: 10.1111/apt.14473.
55. Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. *Lancet Diabetes Endocrinol*. 2019;7:313-324. doi: 10.1016/S2213-8587(18)30154-2. Epub 2018 Aug 30. Review.
56. Khan R, Bril F, Newsome PN, Cusi K. Modulation of insulin resistance in NAFLD. *Hepatology*. 2019;70:711-724.
57. Akshintala D, Chugh R, Amer F, Cusi K. Nonalcoholic fatty liver disease: The overlooked complication of type 2 diabetes. In: Feingold KR, Anawalt B, Boyce A, et al (editors). In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–2019 Jul 9. PMID: 31310460 NBK544043 [bookaccession].
58. Cusi K. Incretin-based therapies for the management of nonalcoholic fatty liver diesease in patients with type 2 diabetes. *Hepatology*. 2019;69:2318-2322.
59. Cusi K. Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes. Diabetes Care. 2020;43:275-279.
60. Budd J, Cusi K. Non-alcoholic fatty liver disease: What does the primary care physician need to know? Am J Med. 2020;133:536-543.

61. Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep. 2019;1:312-328.
62. Cusi K. A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. Liver Int. 2020;40, Suppl 1:82-88.
63. Francque S, Szabo G, Abdelmalek M, Byrne C, Cusi K, Dufour J-F, Roden M, Sacks F, Tacke F. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol 2021:18, 24–39.
64. Budd J, Cusi K. Role of Agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease. Current Diabetes Reports 2020;20:59.
65. K Cusi, Sattar N, García-Pérez L-E, Pavo I, Yu M, Robertson KE, Karanikas CA, Haupt A. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diabet Med 2018;35:1434-1439.
66. Arrese et al. Latin American Association for the Study of the Liver (ALEH) Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. Annals of Hepatology 2020;19:674–690.
67. González Ballerga E, Curia A, Cusi K. Update on NAFLD. Acta Latinoamericana 2020 (in press)
68. Cusi K. Fatty Liver Disease: An underdiagnosed complication of type 2 diabetes. Published on the NIDDK website: https://www.niddk.nih.gov/health-information/professionals/diabetes-discoveries-practice/fatty-liver-disease-an-underdiagnosed-complication-of-type-2-diabetes (November 19, 2020).
69. Cusi K, Godinez Leiva E. Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart. Curr Opin Lipidol. 2020;31:364-366.
70. Albogami Y, Cusi K, Daniels MJ, Wei YJ, Winterstein AG. Response to Comment on Albogami et al. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352. Diabetes Care. 2021 Aug;44(8):e167. doi: 10.2337/dci21-0024.
71. Kanwal F, Shubrook J, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison S, Mantzoros C, Klein S, Eckel RH, Kruger, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Gastroenterology 2021;161:1030–1042.e8;
72. Kanwal F, Shubrook J, Adams LA, Pfotenhauer K, Wong VW-S, Wright E, Abdelmalek M, Harrison SA, Loomba R, Mantzoros C, Bugianesi E, Eckel RH, Kaplan L, El-Serag H, Cusi K. Diabetes Care. 2021;44:2162-2172.
73. Kanwal F, Shubrook J, Adams LA, Pfotenhauer K, Wong VW-S, Wright E, Abdelmalek M, Harrison SA, Loomba R, Mantzoros C, Bugianesi E, Eckel RH, Kaplan L, El-Serag H, Cusi K. Obesity (Silver Spring). 2021;29:1401-1412.
74. Kanwal F, Shubrook J, Adams LA, Pfotenhauer K, Wong VW-S, Wright E, Abdelmalek M, Harrison SA, Loomba R, Mantzoros C, Bugianesi E, Eckel RH, Kaplan L, El-Serag H, Cusi K. Metabolism 2021;122:154822.
75. Kanwal F, Shubrook J, Adams LA, Pfotenhauer K, Wong VW-S, Wright E, Abdelmalek M, Harrison SA, Loomba R, Mantzoros C, Bugianesi E, Eckel RH, Kaplan L, El-Serag H, Cusi K. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161:1657-1669.

76. Kanwal F, Shubrook JH, Cusi K. Reply. Gastroenterology. 2022;162:2132-2134.
77. Patel Chavez, Cusi K, Kadiyala S. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. J Clin Endocrinol Metab. 2022;107:29-38. doi: 10.1210/clinem/dgab578.
78. Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10:284-296.
79. Wyne KL, Litwin SE, Cusi K, Guyton JR. JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. J Clin Lipidol Mar-Apr 2022;16(2):115-127.
80. Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022;28:528-562.
81. Cusi K. A simple test to identify the risk of NASH and cirrhosis in people with obesity or diabetes: The time to screen is now. J Clin Endocrinol Metab. 2022 Jun 16;107:e3076-e3077.
82. Barb D, Cusi K. Response to: "Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?". Obesity (Silver Spring). 2022 May;30(5):971-972.
83. Wong VWS, Zelber-Sagi S, Cusi K, Carrieri P, Wright E, Crespo J, Lazarus JV. Management of NAFLD in primary care settings. Liver Int. 2022 Aug 20. doi: 10.1111/liv.15404. Epub ahead of print. PMID: 35986897.

b) Original publications in peer-reviewed journals:

84. Arem R, Cusi K, Kiefe C. Value of sensitive thyrotropin measurement in ambulatory and hospitalized patients. *Clinical & Investigative Medicine*. 1990;13:132-138.
85. Cusi K, Cunningham G, Comstock JP. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. *Diabetes Care*. 1995;18:843-851.
86. Mandarino LJ, Prinz RL, Cusi K, Kinchington P, O'Doherty RM, Osawa H, Sewell C, Consoli A, Granner DK, DeFronzo RA. Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle. *Am J Physiol*. 1995;269:E701-708.
87. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in non-insulin dependent diabetes mellitus. *J Clin Endocrinol Metab*. 1996;81: 4059-4067.
88. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pranawatapatr T, DeFronzo RA, Kahn CR, Mandarino L. Insulin resistance differentially affects the PI 3-kinase and MAP kinase pathways of insulin receptor signaling in human muscle. *J Clin Invest*. 2000; 105: 311-320.
89. Osman AA, Pendergrass M, Koval J, Maezono K, Cusi K, Pratipanawatr T, Mandarino LJ. Regulation of MAP kinase pathway activity in vivo in human skeletal muscle. *Amer J Physiol*. 2000;278: E992-999.
90. Cusi K, DeFronzo RA. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. *J Clin Endocrinol Metab*. 2000;85: 3077-3084.

91. Cusi K, Cukier S, DeFronzo RA, Pereira Redondo JC, Torres M. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. *J Clin Endocrinol Metab*. 2001;86: 1410-1417.
92. Cusi K, Pranawatapatr T, Koval J, Printz R, Ardehali H, Granner DK, DeFronzo RA, Mandarino L. Exercise increases hexokinase II mRNA, but not activity in obesity and type 2 diabetes. *Metabolism*. 2001;50: 602-606.
93. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferranini E, Cusi K, Mandarino L, DeFronzo RA. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. *Diabetes Care*. 2001;24:710-719.
94. Iozzo P, Pranawatapatr T, Pijl H, Vogt C, Kumar V, Pipek R, Matsuda M, Mandarino L, Cusi K, DeFronzo RA. Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis. *Am J Physiol*. 2001;280:E712-E719.
95. Pratipanawatr W, Pratipanawatr T, Cusi K, Berria R, Adams JM, Jenkinson CP, Maezono K. DeFronzo RA, Mandarino LJ. Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation. *Diabetes*. 2001;50: 2572-2578.
96. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mandarino LJ, DeFronzo RA. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetics. *Diabetologia*. 2001;44:2210-2219.
97. Pratipanawatr T, Cusi K, Ngo P, Pratipanawatr W, Mandarino LJ, DeFronzo RA. Normalization of plasma glucose by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes. *Diabetes*. 2002;51:462-468.
98. Pratipanawatr T, Pratipanawatr W, Rosen C, Berria R, Bajaj M, Cusi K, Mandarino LJ, Kashyap S, Belfort R, DeFronzo RA. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. *Am J Physiol*. 2002;282:E1360-1368.
99. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino L, DeFronzo RA. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. *J Clin Endocrinol Metab*. 2002;87:2784-2791.
100. Bajaj M, Berria R, Pratipanawatr T, Kashyap S, Pratipanawatr W, Belfort R, Cusi K, Mandarino L, DeFronzo RA. Free fatty acid-induced peripheral insulin resistance augments splanchnic glucose uptake in healthy humans. *Amer J Physiol*. 2002;283:E346-352.
101. Bajaj M, Pratipanawatr T, Berria R, Pratipanawatr W, Kashyap S, Cusi K, Mandarino L, DeFronzo. Free Fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes. *Diabetes*. 2002;51:3043-3048.
102. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K. A sustained increase in plasma free fatty acids impairs insulin secretion in non-diabetic subjects genetically predisposed to type 2 diabetes. *Diabetes*. 2003;52:2461-2474.
103. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Mandarino L, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finalyson J, Kahn CR. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. *Proc Nat Acad Science*. 2003;100:8466-8471.

104. Civitarese AE, Jenkinson CP, Richardson D, Bajaj M, Cusi K, Kashyap S, Berria R, Belfort R, DeFronzo R, Mandarino LJ, Ravussin E. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes. *Diabetologia*. 2004;47:816-820.
105. Kashyap SR, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, Barrentine A, Bajaj M, Mandarino L, DeFronzo R, Cusi K. Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. *Am J Physiol*. 2004;287:E537-546.
106. Bajaj M, Suraamornkul S, Kashyap SR, Cusi K, Mandarino L, DeFronzo R. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with a strong family history of type 2 diabetes. *J Clin Endo Metab*. 2004;89:4649-4655.
107. Belfort R, Mandarino L, Kashyap S, Wirfel K, Berria R, Pratipanawatr T, DeFronzo RA, Cusi K. Dose response effect of elevated plasma FFA on insulin signaling. *Diabetes*. 2005;54: 1640-1648.
108. Richardson DK, Kashyap S, Bajaj M, Cusi K, Mandarino SJ, Finlayson J, DeFronzo RA, Jenkinson CP, Mandarino LJ. Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. *J Biol Chem*. 2005;280:10290-10297.
109. Ruan C, Yang S, Clarke GD, Amurao MR, Partyka S, Bradley Y, Cusi K. First-pass contrast-enhanced myocardial perfusion MRI using a maximum upslope parametric map. *IEEE Trans Inf Technol Biomedicine*. 2006;10:574-580.
110. Belfort, R, Harrison S, Brown K, Darland C, Finch J, Balas B, Gastaldelli A, Tio F, Hardies J, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo RA, Bannayan GA, Schenker S, Cusi K. A placebo controlled trial of pioglitazone in patients with non-alcoholic steatohepatitis (NASH). *New Engl J Med*. 2006;355:2297-2307.
111. DeFilippis E, Cusi K, Fernandez M, Mandarino L. Exercise improves endothelial function in type 2 diabetes. *J Clin Endocrinol Metab*. 2006;91:4903-4910.
112. Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo RA. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome*. Clin Pharmacology & Therapeutics.* 2006; 80:105-114.
113. Cusi K, Kashyap S, Belfort R, Bajaj M, Cersosimo E, Lee, S. Effects on insulin secretion and action of short-term reduction of plasma free fatty acids with acipimox in non-diabetic subjects genetically predisposed to type 2 diabetes. *Am J Physiol*. 2007;292:E1775-1781.
114. Balas B, BaigM, Watson C, Dunning B, Ligueros-Saylan M, He Y, Wang Y, Holst J, Deacon C, Cusi K, Mari A, Foley J, DeFronzo RA. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. *J Clin Endocrinol Metab*. 2007;92:1249-1255.
115. Berria R, Glass L, Mahankali A, Miyazaki Y, Monroy A, De Filippis E, Cusi K, Cersosimo E, DeFronzo RA, Gastaldelli A. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in T2DM. *Clin Pharmacology & Therapeut*. 2007;82:275-281.

116. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi A, Cersosimo E, Ferrannini E, and DeFronzo R. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. *Gastroenterology*. 2007;133:496-506.
117. Balas B, Belfort R, Harrison, S, Darland C, Finch J, Schenker S, Gastaldelli A, Cusi K. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. *J Hepatology*. 2007;47:565-570.
118. Ruan C, Yang S, Cusi K, Gao F, Clarke GD. Contrast-enhanced first-pass myocardial perfusion MRI with parallel acquisition at 3.0 Tesla. *Investigative Radiology*. 2007;42:352-360.
119. Fernandez M, Triplitt C, Wajcberg E, Sriwijilkamol A, Musi N, Cusi K, DeFronzo RA, Cersosimo E. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. *Diabetes Care*. 2008;31:121-127.
120. De Filippis E, Alvarez G, Berria R, Cusi K, Everman S, Meyer C, Mandarino L. Insulin-resistant muscle is exercise resistant: evidence for reduced response of nuclear-encoded mitochondrial genes to exercise. *Am J Physiol*. 2008;294:E607-614.
121. Positano V, Cusi K, Santarelli MF, Sironi A, Petz R, Defronzo R, Landini L, Gastaldelli A. Automatic correction of intensity inhomogeneities improves unsupervised assessment of abdominal fat by MRI. *J Magn Reson Imaging*. 2008;28:403-410.
122. Kashyap S, Belfort R, Cersosimo, E, Lee S, Cusi K. Chronic low-dose lipid infusion in healthy subjects induces markers of endothelial activation independent of its metabolic effects. *J Cardiometabolic Syndrome*. 2008;3:141-146.
123. Balas B. Wang S. Cusi K. Allergic skin reaction to insulin detemir: Resolution with continued use. *Endocrine Practice*. 2008;14:796-797.
124. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven P and the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. *New England J Med*. 2009;360:129-139.
125. Nicholas E, Klein R, Moritz T, Davis MD, Glander K, Anderson R and the VADT Investigators. Comparison of dilated fundus examinations with seven-field stereo fundus photographs in the Veterans Affairs Diabetes Trial. *J Diabetes Complications*. 2009;23:323-329.
126. Gastaldelli A, Harrison S, Belfort R, Hardies J, Balas, B, Schenker S, Cusi K. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. *Hepatology*. 2009;50:1087-1093.
127. Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. *J Clin Endocrinol Metab*. 2010;95:829-836.
128. Mathew M, Tay E, Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. *Cardiovascular Diabetology*. 2010;16:9.
129. Jones P, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep D, Stolzenbach JC. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in

patients with mixed dyslipidemia and type 2 diabetes mellitus: Results from a pooled subgroup analysis from three randomized, controlled, double-blind trials. *Amer J Cardiovascular Drugs*. 2010;10:73-84.
130. Glass L, Cusi K, Berria R, Petz R, Cersosimo E, DeFronzo RA, Gastaldelli A. Pioglitazone improvement of fasting and postprandial hyperglycemia in Mexican-American patients with type 2 diabetes: A double tracer OGTT study. *Clinical Endocrinology.* 2010;73:339-345.
131. Gastaldelli A, Harrison S, Belfort-Aguiar, A, Hardies J, Balas B, Schenker S, MD, Cusi K. Pioglitazone in the treatment of NASH: Role of adiponectin. *Alimentary Pharmacology & Therapeutics*. 2010;32:769-775.
132. Wang S, Kamat A, Pergola P, Swamy A, Tio F, Cusi K. Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression *in vivo*. *MetabolismI.* 2011; 60:1090-1099.
133. Ortiz-Lopez C, Policarpio-Nicolas ML, Cusi K. Effect of pioglitazone in a patient with impaired glucose tolerance and NASH. *Diabetes Management.* 2011 Aug.
134. Lomonaco R, Ortiz-Lopez C, Orsak B, Finch J, Webb A, Bril F, Louden C, Tio F, Cusi K. Role of ethnicity in overweight and obese subjects with nonalcoholic steatohepatitis (NASH). *Hepatology*. 2011;54:837-845.
135. Duckworth WC, Abraira C, Moritz TE, Davis SN, Emanuele N, Goldman S, Hayward R, Huang GD, Marks JB, Reaven PD, Reda DJ, Warren SR, Zieve FJ; Investigators of the VADT. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: The VA Diabetes Trial. *J Diabetes Complications.* 2011;25:355-361.
136. Zhou A, Murillo H, Cusi K, Peng Q. Comparison of visceral adipose tissue quantification on water suppressed and nonwater-suppressed MRI at 3.0 Tesla*. J Magn Reson Imaging.* 2012;35:1445-1452.
137. Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, Finch J, Gastaldelli A, Harrison S, Tio F, Cusi K. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in patients with NAFLD. *Hepatology*. 2012;55:1389-1397.
138. Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov V, Hardies J, Cusi K. Prevalence of prediabetes and diabetes and metabolic profile of patients with NAFLD. *Diabetes Care*. 2012;35:873-8.
139. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Hepatology*. 2012;55:2005-2023.
140. Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, Ortiz-Lopez C, Hecht J, Feldstein AE, Webb A, Louden C, Goros M, Tio F. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. *J Hepatology*. 2013;60:167-174.
141. Bril F, Lomonaco R, Orsak B, Ortiz-Lopez C, Webb A, Tio F, Hecht J, Cusi K. Relationship between disease severity, hyperinsulinemia and impaired insulin clearance in patients with nonalcoholic steatohepatitis (NASH). *Hepatology*. 2013;59:2178-2187.
142. Portillo P, Yavuz S, Bril F, Cusi K. Role of insulin resistance and diabetes in the pathogenesis and treatment of NAFLD. *Curr Hepatol Reports.* 2014;13:159-170.

143. Kawaguchi-Suzuki M, Bril F, Portillo Sanchez P, Cusi K, Frye RF. A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2014;969:219-223.
144. Cusi, K. The relationship between hepatitis C virus infection and diabetes: Time for a divorce? *Hepatology*. 2014;60:1121-1123.
145. Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, Suman A, Weber M, Cusi K., The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. *Hepatology*. 2015;61:153-160.
146. Bril F, Maximos M, Portillo-Sanchez P, Biernacki D, Lomonaco R, Subbarayan S, Correa M, Lo M, Suman A, Cusi K. Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. *J Hepatol*. 2015;62:405-411.
147. Turner JR, Schatz DA, Cusi K, Strumph P. Healthcare transition from pediatric to adult medical homes in diabetes mellitus. *Endocr Pract*. 2014;20:714-20.
148. Zavitsamos P, Amdur RJ, Drew PA, Cusi K, Werning JW, Morris CG. Favorable outcome of hurthle cell carcinoma of the thyroid treated with total thyroidectomy, radioiodine and selective use of external-beam radiotherapy. *Am J Clin Oncol*. 2015.
149. Bril F, Ortiz-Lopez C, Lomonaco R, Orsak B, Freckleton M, Chintapalli K, Hardies J, Lai S, Solano F, Tio F, Cusi K. Clinical value of liver ultrasound for the diganosis of nonalcoholic fatty liver disease in overweight and obese patients. *Liver Intl.* 2015;35:2139-2146.
150. Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J, Cusi K. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. *J Clin Endocrinol Metab* 2015 June;100(6):2231-2238. Doi: org/10.1210/jc.2015-1966.
151. Bril F, Cusi K. Response to do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent? *Liver Intl*. 2015;35(10):2341-2342. doi:10.1111/liv.12869.
152. Sunny NE, Kalavalapalli S, Bril F, Garrett TJ, Nautiyal M, Mathew JT, Williams CM, Cusi K,. Cross-talk between branched-chain amino acids and hepatic mitochondria is comprised in nonalcoholic fatty liver disease. *Am J Physiol Endocrinol Metab*. 2015;309(4):E311-319. doi:10.1152/ajpendo.00161.2015.
153. Bril F, Sninsky JJ, Baca AM, Superko HR, Portillo-Sanchez P, Biernacki D, Maximos M, Lomonaco R, Orsak B, Suman A, Weber MH, McPhaul MJ, Cusi K,. Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. *J Clin Endocrinol Metab*. 2016;101:644-652. doi: 10.1210/jc.2015-3111.
154. Bril F, Kadiyala S, Portillo-Sanchez P, Sunny NE, Biernacki D, Maximos M, Kalavalapalli S, Lomonaco R, Suman A, Cusi K. Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes. *J Invest Med.* 2016;64(1):63-68. doi:10.1136/jim-2015-000019.
155. Patterson RE, Kalavalapalli S, Williams CM, Nautiyal M, Mathew JT, Martinez J, Reinhard MK, McDougall DJ, Rocca RJ, Yost RA, Cusi K, Garrett TJ, Sunny NE.Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. *Am J Physiol Endocrinol Metab*. 2016;310(7):E484-94. doi:10.1152/ajpendo.00492.2015.

156. Lomonaco R, Bril F, Portillo-Sanchez P, Ortiz-Lopez C, Orsaki B, Biernacki D, Lo M, Suman A, Weber MH, Cusi K. Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes. *Diabetes Care*. 2016 Apr;39(4):632-8. doi:10.2337/dc15-1876.
157. Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, Tio F, Hardies J, Darland C, Musi N, Webb A, Portillo-Sanchez P. Long-term pioglitazone treatment for patients with NASH and prediabetes or type 2 diabetes mellitus: a randomized controlled trial. *Ann Intern Med.* 2016;165:305-15. doi:10.7326/M15-1774.
158. Cusi K, Sanyal AJ, Zhang S, Hoogwerf BJ, Chang AM, Jacober SJ, Bue-Valleskey JM, Higdon AN, Bastyr EJ III, Haupt A and Hartman ML. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. *Diabetes Obes Metab*. 2016;18(2):50–58. doi: 10.1111/dom.12751.
159. Zimering MB, Knight J, Ge L, Bahn G; VADT Investigators. Predictors of cognitive decline in older adult type 2 diabetes from the Veterans Affairs Diabetes Trial. *Front Endocrinol* (Lausanne). 2016 Sep 8;7:123. doi: 10.3389/fendo.2016.00123. eCollection 2016.
160. Bril F, Barb D, Portillo-Sanchez P, Biernacki D, Lomonaco R, Suman A, Weber MH, Budd JT, Lupi ME, Cusi K. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. *Hepatology*. 2017;65(4):1132-1144. doi:10.1002/hep.28985.
161. Kawaguchi-Suzuki M, Cusi K, Bril F, Gong Y, Langaee T, Frye R. A genetic response score for pioglitazone use in patients with nonalcoholic steatohepatitis. *Front Pharmacol*. 2018 July;9:56-61. doi: 10.3389/fphar.2018.00752.
162. Kawaguchi-Suzuki M, Bril F, Kalavalapalli S, Cusi K, Frye RF. Concentration-dependent response to pioglitazone in nonalcholic steatohepatitis. *Aliment Pharmacol Ther*. 2017 July;46(1):56-61. doi:10.1111/apt.14111.
163. Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, Haupt A. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. *Diabetes Obes Metab*. 2017;19:1630-1634. doi: 10.1111/dom.12973.
164. Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Hecht J, Tio F, Cusi K. Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: Post-hoc analysis of a randomized trial. *J Clin Endocrinol Metab*. 2017 Aug;102(8):2950-2961.
165. Newton CA, Sheehan E, Wyne K, Cusi K, Leey J, Ghayee HK. The Yin and Yang Between plasma glucose levels and cortisol replacement therapy in Schmidt's syndrome. *J Investig Med High Impact Case Rep*. 2017 Jul 6;5(3). doi:10.1177/2324709617716203.
166. Barritt AS Th, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, Powell M, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal A. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Contemp Clin Trials. 2017 Jul;61:33-38. doi:10.1016/j.cct.2017.07.015.
167. Bril F, Portillo-Sanchez P, Lomonaco R, Liu IC, Kalavalapalli S, Dayton K, Cusi K. Clinical and histologic characterization of nonalcoholic steatohepatitis in African American patients. *Diabetes Care*. 2018 Jan;41(1):187-192. doi:10.2337/dc17-1349.
168. Sanyal A, Cusi K, Hartman ML, Zhang S, Bastyr EJ 3rd, Bue-Vallesky JM, Change AM, Haupt A, Jacober SJ, Konard RJ, Zhang Q, Hoogwerf BJ. Cytokeratin-18 and enhanced

liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins. *J Investig Med*. 2018 Mar;66(3):661-668.
169. Bril F, Kalavalapalli S, Clark VC, Lomonaco R, Soldevilla-Pico C, Liu IC, Orsak B, Tio F, Cusi K. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. *Clin Gastroenterol Hepatol*. 2018 Apr;16(4):558-566.
170. Bril F, Millan L, Kalavalapalli S, McPhaul MJ, Caufield MP, Martinez-Arranz I, Alonso C, Ortiz Betes P, Mato JM, Cusi K. Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. *Diabetes Obes Metab*. 2018 July;20(7):17021709. doi:10.111/dom.13285.
171. Kalavalapalli S, Bril F, Koemel JP, Abdo K, Guingab J, Andrews P, Li WY, Jose D, Yost RA, Frye RF, Garrett TJ, Cusi K, Sunny NE. Pioglitazone improves hepatis mitochondrial function in a mouse model of nonalcoholic steatohepatitis. *Am J Physiol Endpcrinol Metab*. 2018 Aug;315(2):E163-173.
172. Cusi K, Sattar N, García-Pérez L-E, et al. Dulaglutide decreases plasma aminotransferases in people with type 2 diabetes in a pattern consistent with liver fat reduction: A post hoc analysis of the AWARD Programme. *Diabetic Medicine*. 2018;35:1434.1439.
173. Kawaguchi-Suzuki M, Cusi K, Bril F, Gong Y, Langaee T, Frye RF. A genetic score associates with pioglitazone response in patients with nonalcoholic steatohepatitis. *Front Pharmacol*. 2018 Jul 17;9:752. doi:10.3389/fphar.2018.00752. eCollection 2018.94.
174. Portillo-Sanchez P, Bril F, Lomonaco R, Barb D, Orsak B, Bruder JM, Cusi K. Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial. *J Diabetes*. 2019:11:223-231.
175. Bril F, Cusi K. Response to Comment: Bril et al: Clinical and histologic characterization of nonalcoholic steatohepatitis in African American patients. *Diabetes Care*. 2018;41:187-192.
176. Bril F, McPhaul MJ, Caulfield MP, Castille JM, Poynard T, Soldevila-Pico C, Clark VC, Firpi-Morell RJ, Lai J, Cusi K. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. *J Investig Med*. 2019 ;67:303.311.
177. Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, Farrell K, Sunny NE, Kalavalapalli S, Pettus J, Ciaraldi TP, Mudaliar S, Henry RR. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. *Diabetes Obes Metab*. 2019;21:812-821.
178. Hwang CL, Lim J, Yoo JK, Kim HK, Hwang MH, Handberg EM, Petersen JW, Holmer BJ, Leey Casella J, Christou DD, Cusi K. Effect of all-extremity high-intensity interval training vs. moderate-intensity continous training on aerobic fitness in middle-aged and older adults with type 2 diabetes: A randomized controlled trail. *Exp Gerontol*. 2019 Feb;116:46-53.
179. Bril F, Kadiyala S, Cusi K. Re: “Association between primary hypothyroidism and nonalcholic fatty liver disease: A systematic review and meta-analysis” by Mantovani et al. (Thyroid 2018;28:1270-1284. *Thyroid*. 2019;29:452.
180. Barb D, Bril F, Kalavalapalli S, Cusi K. Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes. *J Clin Endocrinol Metab*. 2019; 104:3327-3336.
181. Fernando H, Cohen R, Gullett J, Friedman J, Ayzengart A, Porges E, Woods A, Gunstad J, Ochoa C, Cusi K, Gonzalez-Louis R, Donahoo T. Neurocognitive deficits in a cohort with

class 2 and class 3 obesity: Contributions of type 2 diabetes and other comorbidities. *Obesity*. 2019;27:1-8.
182. Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J, Tio F, Suman A, Orsak BK, Hecht J, Cusi K. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: A randomized controlled trial. Diabetes Care. 2019;42:1481-1488.
183. Kalavalapalli S, Bril F, Guingab J, Vergara A, Garrett TJ, Sunny NE, Cusi K. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. *J Endocrinol*. 2019;241:293-305.
184. Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, Duckworth WC, Hayward RA; VADT Investigators. Intensive glucose control in patients with type 2 diabestes – 15-year follow up. *N Engl J Med*. 2019;380:2215-2224.
185. Bril F, Leeming DJ, Karsdal MA, Kalavalapalli S, Barb D, Lai J, Rabe M, Cusi K. Use of plasma fragments of propeptides of tye III, V, and VI procollagen for the detection of liver fibrosis in type 2 diabetes. *Diabetes Care*. 2019 Jul;42:1348-1351
186. Bril F, Cusi K. Hepatic insulin extraction in NAFLD is related to insulin resistance rather than iver fat content. *J Clin Endocrinol Metab*. 2019;104:5249-5250.
187. Colomba J, Netedu SR, Lehoux-Dubois C, Coriati A, Boudreau V, Tremblay F, Cusi K, Rabasa-Lhoret R, Leey JA. Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis. PLoS One. 2019 Jul 18;14:e0219855. doi: 0.1371/journal.pone.0219855. eCollection 2019.
188. Agrawal L, Azad N, Bahn GD, Reaven PD, Hayward RA, Reda DJ, Emanuele NV; VADT Study Group. Intensive glycemic control improves long-term renal outcomes in type 2 diabetes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2019;42:e181-e182.
189. Bril F, Barb D, Lomonaco R, Lai J, Cusi K. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. J Hepatol. 2020;72:401-410.
190. Bril F, McPhaul MJ, Caulfield MP, Clark VC, Soldevilla-Pico C, Firpi-Morell RJ, Lai J, Shiffman D, Rowland CM, Cusi K. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes. Diabetes Care. 2020;43:290-297.
191. Mizokami-Stout KR, Li Z, Foster NC, Shah V, Aleppo G, McGill JB, Pratley R, Toschi E, Ang L, Pop-Busui R; for T1D Exchange Clinic Network; T1D Exchange Clinic Network. The contemporary prevalence of diabetic neuropathy in type 1 diabetes: Findings from the T1D exchange. Diabetes Care. 2020;43:806-812.
192. Miller KM, Hermann J, Foster N, Hofer SE, Rickels MR, Danne T, Clements MA, Lilienthal E, Maahs DM, Holl RW; T1D Exchange and DPV Registries Longitudinal Changes in Continuous Glucose Monitoring Use Among Individuals With Type 1 Diabetes: International Comparison in the German and Austrian DPV and U.S. T1D Exchange Registries. Diabetes Care. 2020;43(1):e1-e2.
193. Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. J Hepatol. 2020;72:613-626.

194. Rai SK, Bril F, Hatch HM, Xu Y, Shelton L, Kalavalapalli S, Click A, Lee D, Beecher C, Kirby A, Kong K, Trevino J, Jha A, Jatav S, Kriti K, Luthra S, Garrett TJ, Guingab-Cagmat J, Plant D, Bose P, Cusi K, Hromas RA, Tischler AS, Powers JF, Gupta P, Bibb J, Beuschlein F, Robledo M, Calsina B, Timmers H, Taieb D, Kroiss M, Richter S, Langton K, Eisenhofer G, Bergeron R Jr, Pacak K, Tevosian SG, Ghayee HK. Targeting pheochromocytoma and paraganglioma with polyamine inhibitors. Metabolism. 2020;110:154297.
195. Harrison SA, Calanna S, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal A, Sejling A-S, Newsome PN. Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. Contemporary Clinical Trials 2020;97:106174. doi: 10.1016/j.cct.2020.106174.
196. Sattari M, Bril F, Egerman R, Kalavalapalli S, Cusi K. Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy. J Investig Med. 2020;68:743-747.
197. Lazarus JV, Anstee MQ, Hagström H, Cusi K, Cortez-Pinto H, Mark HE, Roden M, Tsochatzis E, Villota M, Wong V, Younossi Z, Zelber-Sagi S, Romero-Gómez M, Schattenberg JM. Defining comprehensive novel models of care for NAFLD. Nat Rev Gastroenterol Hepatol 2021; 8:717-729.
198. Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, Portillo Romero J, Schmidt S, Chang K, Samraj G, Malaty J, Huber K, Bedossa P, Kalavalapalli S, Marte J, Barb D, Poulton D, Fanous N, Cusi K. Advanced liver fibrosis is common in patients with type 2 diabetes mellitus followed in the outpatient setting: The need of systematic screening. Diabetes Care, 2021;44:399-406.
199. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling A-S, Harrison S, NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. NEJM 2021;384:1113-1124.
200. Barritt AS, Watkins S, Gitlin N, Klein S, Lok AS, Loomba R, Schoen C, Reddy KR, Trinh HN, Mospan AR, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Hepatology Communications 2021;0:1-9.
201. Julián MT, Pera G, Soldevila B, Caballería L, Julve J, Puig C, Morillas R, Torán P, Expósito C, Puig-Domingo M, Franch-Nadal J, Cusi K, Mauricio D, Alonso N. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: A population–based study. Eur J Endocrinol. 2021;184:587-596.
202. Amole M, Leey J, Cusi K. Real-world experience with automated insulin pump technology in Veterans with type 1 diabetes. Federal Practitioner Amole M, Whyte L, Ghayee HK, Bril F, Cusi K, Leey-Casella J. Real-World Experience With Automated Insulin Pump Technology in Veterans With Type 1 Diabetes. Fed Pract. 2021;38(Suppl 4):S4-S8. doi: 10.12788/fp.0156.
203. DeBoer MD, Lin B, Filipp S, Cusi K, Gurka. Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis. Nutr Res. 2021;88:34-43.
204. Albogami Y, Cusi K, Daniels MJ, Wei YJJ, Winterstein AG. Glucagon-like peptide-1 receptor agonists and chronic lower respiratory disease exacerbations among patients with type 2 diabetes. Diabetes Care 2021;44:1344-1352.

205. Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-α/γ Agonist, for treatment of nonalcoholic fatty liver disease: A randomized controlled double-blind phase 2 trial. Hepatology. 2021;74:1809-1824.
206. Dayton K, Bril F, Barb D, Lai J, Kalavalapalli S, Cusi, K. Severity of NASH is not linked to testosterone concentration in patients with type 2 diabetes. PLoS One 2021 Jun 2;16:e0251449. doi: 10.1371/journal.pone.0251449. eCollection 2021.
207. Gastaldelli A, Sabatini S, Carli F, Gaggini M, Bril F, Belfort-DeAguiar R, Positano V, Barb D, Kadiyala S, Harrison S, Cusi K. PPAR-γ-induced improvement of NASH are associated with decrease in visceral fat and increase in adiponectin levels. Liver International 2021;41:2659-2670.
208. Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. Obesity (Silver Spring). 2021;29:1950-1960.
209. Bril F, McPhaul, MJ, Kalavapalli S, Lomonaco R, Barb D, Meagan G, Shiffman D, Rowlan CM, Cusi K. Intact fasting insulin identifies nonalcoholic fatty liver disease in patients without diabetes. J Clin Endocrinol Metab. 2021;106:e4360-e4371.
210. Kim HP, Idowu MO, Mospan AR, Allmon AG, Roden M, Newsome P, Lok AS, Thuluvath PJ, Taunk J, Fried MW, Sanyal AJ, Barritt AS 4th; TARGET-NASH Investigators. Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Aliment Pharmacol Ther. 2021;54:1472-1480. doi: 10.1111/apt.16674.
211. Cusi K, Alkhouri N, Harrison SA, Fouqueray P, Moller DE, Hallakou-Bozec S, Bolze S, Grouin JM, Jeannin Megnien S, Dubourg J, Ratziu V. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Gastroenterol Hepatol. 2021;6:889-902.
212. Fouqueray P, Bolze S, Dubourg J, Hallakou-Bozec S, Theurey P, Grouin JM, Chevalier C, Gluais-Dagorn P, Moller DE, Cusi K. Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study. Cell Rep Med. 2021;2:100474.
213. Tang H, Kimmel SE, Hernandez I, Brooks MM, Cusi K, Smith SM, Shi W, Winterstein AG, Magnani JW, Guo J. Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrollment. Diabetes Obes Metab. 2022;24:154-159.
214. Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K; Martínez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Mincholé I, Bizkarguenaga M, Arretxe E, Iruarrizaga-Lejarreta M, Fernández-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sánchez L, Smid V, Arnold J, Iruzubieta P, Pérez Castaño Y, Krawczyk M, Marigorta UM, Morrison MC, Kleemann R, Martín-Duce A, Hayardeny L, Vitek L, Bruha R, Aller de la Fuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, **Cusi K**, Bugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM. Metabolic subtypes of patients with NAFLD exhibit

distinctive cardiovascular risk profiles. Hepatology 2022 Feb 26. doi: 10.1002/hep.32427. Online ahead of print.
215. NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Advancing the global public health agenda for NAFLD: a consensus statement. Rev Gastroenterol Hepatol 2022;19:60-78. doi: 10.1038/s41575-021-00523-4.
216. Tang H, Kimmel SE, Smith SM, Cusi K, Shi W, Gurka M, Winterstein AG, Guo J. Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. Diabetes Obes Metab 2022;24:154-159.
217. Wu Y, Yang X, Morris HL, Gurka MJ, Shenkman EA, Cusi K, Bril F, Donahoo WT. Non-invasive diagnosis of nonalcoholic steatohepatitis and advanced liver fibrosis: using machine learning methods. JMIR Med Inform. 2022;10:e36997.
218. Migdal AL, Jagannathan R, Qayed E, Cusi K, McCoy RG, Pasquel FJ, Miller LS. Association of Obesity, Diabetes, and Alcohol Use With Liver Fibrosis Among US Adults With Hepatitis C Virus Infection. JAMA Netw Open. 2022;5:e2142282.
219. Waddell T, Bagur A, Cunha D, Thomaides-Brears H, Banerjee R, Cuthbertson DJ, Brown E, Cusi K, Després JP, Brady M. Greater ectopic fat deposition and liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes. Obesity (Silver Spring). 2022;30:1231-1238.
220. Bril F, Godinez Leiva E, Lomonaco R, Shrestha S, Kalavalapalli S, Gray M, Cusi K. Assessing strategies to target screening for advanced liver fibrosis among overweight and obese patients. Metab Target Organ Damage. 2022;2:11. doi: 10.20517/mtod.2022.08. Epub 2022 Jul 18. PMID: 36017449; PMCID: PMC9400455.
221. Martínez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Mincholé I, Bizkarguenaga M, Arretxe E, Iruarrizaga-Lejarreta M, Fernández-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sánchez L, Smid V, Arnold J, Iruzubieta P, Pérez Castaño Y, Krawczyk M, Marigorta UM, Morrison MC, Kleemann R, Martín-Duce A, Hayardeny L, Vitek L, Bruha R, Aller de la Fuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, Cusi K, Bugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology. 2022 Feb 26. doi: 10.1002/hep.32427.
222. Dayton K, Bril F, Kachru R, Vanderbilt D, Cusi K.Fibroscan as a screening tool for pediatric non-alcoholic fatty liver disease (NAFLD) in obese adolescents (under review).